Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Guangzhou Gloria Biosciences

Status and phase: Not yet enrolling; Phase 2; Phase 1

Conditions: Advanced Non-Small Cell Lung Cancer

Treatments: Drug: GLS-012+GLS-010; Drug: GLS-012+GLS-010+pemetrexed+carboplatin; Drug: GLS-012+GLS-010+paclitaxel+carboplatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT05978401

GLS-012-21

Details and patient eligibility

About

This is a multicenter, open Phase I/II study. The trial consists of two parts, Part1 is a dose-escalation/expansion study, Part2 is a combination of GLS-010 and GLS-010+GLS-012 with standard chemotherapy for advanced non-small-cell lung cancer respectively to assess preliminary efficacy at the combination dose.

Enrollment: 152 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subjects enroll in the study and sign the Informed Consent Form (ICF);

2. Aged ≥18 years and ≤75 years;

3. histologically or cytologically confirmed advanced non-small cell lung cancer without driver genes (diagnostic criteria refer to AJCC 8th edition of squamous or non-squamous non-small cell lung cancer);

4. Subjects with an Eastern Cooperative Oncology Group (ECOG) score of 0 ~1 for physical status;

5. expected survival ≥ 12 weeks;

6. Subjects with measurable lesions (at least 1 extracranial lesion) according to the Solid Tumor Evaluation Criteria (RECIST v1.1).

7. Subjects provide formalin-fixed, paraffin-embedded tumor tissue blocks or unstained tumor specimen sections (at least 6), either archived or freshly obtained within 5 years prior to the first study treatment (freshly obtained is preferred);

8. Organ function meets the following criteria:

   1. Adequate bone marrow reserve (not acceptable for corrective therapy with hematologic products or cell growth factors administered within 14 days prior to first study dose): absolute neutrophil count ≥ 1.5 x 109/L, platelet count ≥ 90 x 109/L, and hemoglobin ≥ 9 g/dL;
   2. Liver: serum albumin ≥ 3.0 g/dL; total bilirubin ≤ 1.5 times the Upper Limit of Normal (ULN), and ALT and AST ≤ 3 times the ULN (or AST and ALT ≤ 5 × ULN for patients with known liver metastases);
   3. Renal: blood creatinine ≤ 1.25 times ULN;
   4. Heart: left ventricular ejection fraction (LVEF) ≥ 50%.

9. Subjects of childbearing potential must be using highly effective contraception during the study and for at least 6 months after the last dose; female subjects of childbearing potential must have a negative blood pregnancy test within 3 days prior to study enrollment.

Exclusion criteria

1. Severe immunotherapy-related toxicity during prior treatment with anti-ICIs;
2. Prior grade ≥ 3 irAE on immunotherapy and who have not recovered to grade ≤ 1 from the last adverse reaction to antineoplastic therapy;
3. With primary or secondary immunodeficiency；
4. Any active, known or suspected autoimmune disease;
5. Known CNS metastases ;
6. Prior severe allergic reactions to large protein preparations/monoclonal antibodies (CTCAE V5.0 classification ≥ grade 4);
7. Previous treatment with anti-LAG-3 antibodies;
8. Other malignant tumors within 5 years prior to screening, except cured cervical carcinoma in situ and cured basal cell carcinoma of the skin;
9. Have uncontrolled cardiac clinical symptoms or disease；
10. Subjects have received a live attenuated vaccine (except inactivated viral seasonal influenza vaccine and novel coronavirus vaccine) within 4 weeks prior to the first dose and who will not receive intranasally administered live attenuated influenza vaccine;
11. Pregnant or nursing females；
12. Poorly compliant or otherwise unsuitable for participation in this study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

152 participants in 4 patient groups

Phase I Dose-Escalation Stage：GLS-012+GLS-010

Experimental group

Description:

Participants will be treated with escalating doses of GLS-010 + GLS-012 to determine the MTD

Treatment:

Drug: GLS-012+GLS-010

Drug: GLS-012+GLS-010

Phase I Expansion Stage：GLS-012+GLS-010

Experimental group

Description:

Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of GLS-012+GLS-010 in Advanced Non-Small Cell Lung Cancer.

Treatment:

Drug: GLS-012+GLS-010

Drug: GLS-012+GLS-010

GLS-012+GLS-010+pemetrexed + carboplatin

Experimental group

Description:

Participants will be enrolled in the expansion stage to better characterize the safety, PK variability, and preliminary efficacy of GLS-012+GLS-010+pemetrexed+carboplatin in Advanced Non-Small Cell Lung Cancer.

Treatment:

Drug: GLS-012+GLS-010+pemetrexed+carboplatin

GLS-012+GLS-010+paclitaxel+carboplatin

Experimental group

Description:

Participants will be enrolled in the expansion stage to better characterize the safety, PK variability, and preliminary efficacy of GLS-012+GLS-010+paclitaxel+carboplatin in Advanced Non-Small Cell Lung Cancer.

Treatment:

Drug: GLS-012+GLS-010+paclitaxel+carboplatin